PURPOSE: Dihydroartemisinin-piperaquine (DP) is a fixed-dose artemisinin-based combination treatment. Field pharmacokinetic studies would be simplified and facilitated by being able to use small volume capillary assays rather than venous blood. The aim of this study was to describe the relationship between piperaquine concentrations measured in capillary blood, venous blood and venous plasma. METHODS: Samples of plasma, whole blood obtained by venesection and capillary blood were taken simultaneously from patients with uncomplicated Plasmodium falciparum malaria treated with DP between 0 and 9 weeks after treatment. Piperaquine concentrations in venous and capillary samples were measured using solid phase extraction and analysis by liquid chromatography with ultraviolet detection. RESULTS: A total of 161 sets of the three measures were obtained from 54 patients. Piperaquine concentrations in the venous blood samples were approximately twofold higher and those in the capillary blood samples were threefold higher than the corresponding venous plasma concentrations. Capillary blood piperaquine concentrations were approximately 1.7-fold higher than venous blood concentrations, and this difference also increased with time. CONCLUSION: Differences in whole blood and plasma levels of piperaquine suggest compartmentalisation of the drug within blood cells, as also occurs with the structurally related quinoline chloroquine. The relationship between piperaquine concentrations in the venous plasma, venous blood and capillary blood is variable and unpredictable at low concentrations. However, within the range of concentrations usually present in patients between 3 and 21 days after treatment with currently recommended doses, the relationship between capillary and venous whole blood is predictable; consequently, capillary blood sampling can be used in field assessments.
PURPOSE:Dihydroartemisinin-piperaquine (DP) is a fixed-dose artemisinin-based combination treatment. Field pharmacokinetic studies would be simplified and facilitated by being able to use small volume capillary assays rather than venous blood. The aim of this study was to describe the relationship between piperaquine concentrations measured in capillary blood, venous blood and venous plasma. METHODS: Samples of plasma, whole blood obtained by venesection and capillary blood were taken simultaneously from patients with uncomplicated Plasmodium falciparum malaria treated with DP between 0 and 9 weeks after treatment. Piperaquine concentrations in venous and capillary samples were measured using solid phase extraction and analysis by liquid chromatography with ultraviolet detection. RESULTS: A total of 161 sets of the three measures were obtained from 54 patients. Piperaquine concentrations in the venous blood samples were approximately twofold higher and those in the capillary blood samples were threefold higher than the corresponding venous plasma concentrations. Capillary blood piperaquine concentrations were approximately 1.7-fold higher than venous blood concentrations, and this difference also increased with time. CONCLUSION: Differences in whole blood and plasma levels of piperaquine suggest compartmentalisation of the drug within blood cells, as also occurs with the structurally related quinoline chloroquine. The relationship between piperaquine concentrations in the venous plasma, venous blood and capillary blood is variable and unpredictable at low concentrations. However, within the range of concentrations usually present in patients between 3 and 21 days after treatment with currently recommended doses, the relationship between capillary and venous whole blood is predictable; consequently, capillary blood sampling can be used in field assessments.
Authors: Joel Tarning; Niklas Lindegårdh; Anna Annerberg; Thida Singtoroj; Nicholas P J Day; Michael Ashton; Nicholas J White Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191
Authors: J Tarning; Y Bergqvist; N P Day; J Bergquist; B Arvidsson; N J White; M Ashton; N Lindegårdh Journal: Drug Metab Dispos Date: 2006-09-06 Impact factor: 3.922
Authors: M Mayxay; V Thongpraseuth; M Khanthavong; N Lindegårdh; M Barends; S Keola; T Pongvongsa; S Phompida; R Phetsouvanh; K Stepniewska; N J White; P N Newton Journal: Trop Med Int Health Date: 2006-08 Impact factor: 2.622
Authors: J Tarning; I Zongo; F A Somé; N Rouamba; S Parikh; P J Rosenthal; W Hanpithakpong; N Jongrak; N P J Day; N J White; F Nosten; J-B Ouedraogo; N Lindegardh Journal: Clin Pharmacol Ther Date: 2012-01-18 Impact factor: 6.875
Authors: Darren J Creek; Victor Bigira; Shelley McCormack; Emmanuel Arinaitwe; Humphrey Wanzira; Abel Kakuru; Jordan W Tappero; Taylor G Sandison; Niklas Lindegardh; Francois Nosten; Francesca T Aweeka; Sunil Parikh Journal: J Infect Dis Date: 2013-02-27 Impact factor: 5.226
Authors: Carlos J Chaccour; N Regina Rabinovich; Hannah Slater; Sara E Canavati; Teun Bousema; Marcus Lacerda; Feiko Ter Kuile; Chris Drakeley; Quique Bassat; Brian D Foy; Kevin Kobylinski Journal: Malar J Date: 2015-06-11 Impact factor: 2.979
Authors: J Tarning; P Thana; A P Phyo; K M Lwin; W Hanpithakpong; E A Ashley; N P J Day; F Nosten; N J White Journal: CPT Pharmacometrics Syst Pharmacol Date: 2014-08-27